Internet Archive Scholar

COVID-19-vaccination in patients receiving allergen immunotherapy (AIT) or biologics - EAACI recommendations [post]

Marek Jutel, María José Torres, Oscar Palomares, Cezmi Akdis, Thomas Eiwegger, Eva Untersmayr, Domingo Barber Hernández, Magdalena Zemelka-Wiacek, Anna Kosowska, Elizabeth Palmer, Stefan Vieths, Vera Mahler (+57 others)
2021 unpublished

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (153.2 kB)
https://web.archive.org/web/20210716121500/https://d197for5662m48.cloudfront.net/documents/publicationstatus/65430/preprint_pdf/e2b6ecc4bf18042c913e4f135963de6e.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL. The file type is application/pdf.

Immune modulation is a key therapeutic tool for allergic diseases and asthma. It can be achieved in an antigen-specific way via allergen immunotherapy (AIT) or in endotype-driven approach using biologicals that target the major pathways of the type 2 (T2) immune response: IgE, IL-5 and IL-4/IL-13. COVID-19 vaccine provides an excellent opportunity to tackle the global pandemics and is currently being applied in an accelerated rhythm worldwide. It works as well through immune modulation. Thus,
more » ... there is an obvious interference between these treatment modalities recommendations on how they should be applied in sequence are expected. The European Academy of Allergy and Clinical Immunology (EAACI) gathered an outstanding expert panel under its Research and Outreach Committee (ROC). This expert panel was called to evaluate the evidence and formulate recommendation on the administration of COVID-19 vaccine in patients with allergic diseases and asthma receiving AIT or biologicals. The panel also formulated recommendations for COVID-19 vaccine in association with biologicals targeting the type 1 or type 3 immune response. In formulating recommendations, the panel evaluated the mechanisms of COVID-19 infection, of COVID-19 vaccine, of AIT and of biologicals and considered the data published for other anti-infectious vaccines administered concurrently with AIT or biologicals.
doi:10.22541/au.162452341.15060228/v1 fatcat:whacatkdvva4rmkujrqikfiixa
Citation

Marek Jutel, María José Torres, Oscar Palomares, Cezmi Akdis, Thomas Eiwegger, Eva Untersmayr, Domingo Barber Hernández, Magdalena Zemelka-Wiacek, Anna Kosowska, Elizabeth Palmer, Stefan Vieths, Vera Mahler, Giorgio Walter Canonica, Kari Nadeau, Mohamed Shamji, Ioana Agache, Mubeccel Akdis, Musa Khaitov, Alberto Alvarez-Perea, Montserrat Alvaro, Marina Atanasković-Marković, Vibeke Backer, Annick BARBAUD, Sevim Bavbek, Frédéric De Blay, Matteo Bonini, Sergio Bonini, Job van Boven, Knut Brockow, Mario Cazzola, Alexia Chatzipetrou, T. Chivato, A. Cianferoni, Jonathan Corren, Jean-Christoph Caubet, Audrey DunnGalvin, Motohiro Ebisawa, Davide Firinu, Radoslaw Gawlik, Asli Gelincik, Stefano Del Giacco, Charlotte Mortz, H.J. Hoffmann, Karin Hoffmann-Sommergruber, Ludger Klimek, Antti Lauerma, Luis Perez de Llano, Andrea Matucci, Rosan Meyer, André Moreira, Hideaki Morita, Sarita Patil, Oliver Pfaar, Florin-Dan Popescu, VICTORIA DEL POZO, Oliver Price, Ronald van Ree, Montserrat Fernandez-Rivas, Barbara Rogala, Antonino Romano, Alexandra Santos, Anna Sediva, Isabel Skypala, Sylwia Smolinska, Milena Sokolowska, Gunter Sturm, Alessandra Vultaggio, Jolanta Walusiak-Skorupa, Margitta Worm. "COVID-19-vaccination in patients receiving allergen immunotherapy (AIT) or biologics - EAACI recommendations." (2021)